{
    "ticker": "TRVN",
    "name": "Trevena, Inc.",
    "description": "Trevena, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with central nervous system (CNS) disorders. Founded in 2007, Trevena's mission is to create safer and more effective analgesics and other therapeutics by leveraging its unique expertise in G protein-coupled receptor (GPCR) biology. The company is recognized for its lead product candidate, Olinvo (TRV130), a novel analgesic designed to provide pain relief with a potentially reduced risk of addiction compared to traditional opioids. Trevena's proprietary technology platform aims to discover and develop drug candidates that target specific disease mechanisms while minimizing side effects. The company is committed to addressing the opioid crisis by providing alternative treatment options for patients suffering from acute and chronic pain. With a pipeline that includes several promising candidates in various stages of clinical development, Trevena is poised to make a significant impact in the field of pain management and CNS disorders.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "King of Prussia, Pennsylvania, USA",
    "founded": "2007",
    "website": "https://www.trevena.com",
    "ceo": "Carrie B. Cox",
    "social_media": {
        "twitter": "https://twitter.com/TrevenaInc",
        "linkedin": "https://www.linkedin.com/company/trevena-inc/"
    },
    "investor_relations": "https://ir.trevena.com",
    "key_executives": [
        {
            "name": "Carrie B. Cox",
            "position": "CEO"
        },
        {
            "name": "Mark A. S. W. S. S. M. P. P. E. S.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "Olinvo (TRV130)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Trevena, Inc. | Innovative Therapies for CNS Disorders",
        "meta_description": "Explore Trevena, Inc., a clinical-stage biopharmaceutical company focused on developing novel pain management therapies. Learn about their innovative approach to treating CNS disorders.",
        "keywords": [
            "Trevena",
            "Biopharmaceuticals",
            "Pain Management",
            "CNS Disorders",
            "Olinvo",
            "TRV130"
        ]
    },
    "faq": [
        {
            "question": "What is Trevena known for?",
            "answer": "Trevena is known for developing innovative therapies for pain management and CNS disorders, particularly its lead product Olinvo (TRV130)."
        },
        {
            "question": "Who is the CEO of Trevena?",
            "answer": "Carrie B. Cox is the CEO of Trevena, Inc."
        },
        {
            "question": "Where is Trevena headquartered?",
            "answer": "Trevena is headquartered in King of Prussia, Pennsylvania, USA."
        },
        {
            "question": "What are Trevena's main products?",
            "answer": "Trevena's main product is Olinvo (TRV130), a novel analgesic for pain relief."
        },
        {
            "question": "When was Trevena founded?",
            "answer": "Trevena was founded in 2007."
        }
    ],
    "competitors": [
        "NERV",
        "ACOR",
        "PTLA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX"
    ]
}